Genfit(GNFT)

Description: Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

---

Keywords: Medicine Biopharmaceutical Autoimmune Disease Hepatitis Fibrosis Steatohepatitis Non Alcoholic Fatty Liver Disease Hepatology Diagnostic Solutions Cholangiocarcinoma Cirrhosis Primary Biliary Cholangitis

---

Home Page: www.genfit.com

Parc EurasantE
Loos, 59120
France
Phone: 33 3 20 16 40 00

---

Officers

Exchange: PA

Country: FR

Currency: Euro (€)